Key insights
- Nuvation Bio acquired global rights to safusidenib from Daiichi Sankyo, expanding its Phase 3 SIGMA study to Japan. Safusidenib targets IDH1-mutant glioma. While positive clinical trial results could boost Nuvation Bio's stock, the overall impact on the broader US equity market is limited.
NEW YORK - Nuvation Bio Inc. (NYSE:NUVB) amended its license agreement with Daiichi Sankyo (TSE:4568) to acquire Japan rights for safusidenib, giving the company exclusive global development and commercialization rights for the investigational medicine, according to a press release statement issued today. Daiichi Sankyo, with a market capitalization of $33.3 billion, maintains an impressive gross profit margin of 77.54% and has delivered revenue growth of 14.26% over the last twelve months.
The amended agreement allows Nuvation Bio to expand its ongoing Phase 3 SIGMA study of safusidenib into Japan and provides rights to all previously generated and future data supporting publication of safusidenib results in IDH1-mutant glioma. According to InvestingPro analysis, Daiichi Sankyo is a prominent player in the Pharmaceuticals industry and trades at a low P/E ratio of 17.63 relative to near-term earnings growth. The platform reveals 8 additional ProTips for investors evaluating the partnership’s strategic value.
Safusidenib is an oral, brain-penetrant inhibitor of mutant IDH1 currently being evaluated in the Phase 3 SIGMA study for maintenance treatment of patients with IDH1-mutant astrocytoma who have high-risk features following standard-of-care.
In Phase 1 and Phase 2 studies, safusidenib showed efficacy signals across IDH1-mutant glioma grades and treatment lines. A Phase 1 study in Japan enrolled 47 participants with recurrent or progressive IDH1-mutant glioma. Data from a Phase 2 study in Japan of 27 patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant glioma was published in Neuro-Oncology in November 2025, reflecting a March 10, 2023 data cut-off. As of February 2026, 12 patients in the study remain on treatment with a median follow-up of over five years.
The pivotal SIGMA study will evaluate safusidenib compared to placebo as maintenance therapy after standard-of-care in IDH1-mutant astrocytoma with high-risk features, enrolling approximately 300 patients. Data is anticipated in 2029. A separate exploratory cohort will evaluate safusidenib in approximately 40 participants with grade 3 IDH1-mutant oligodendroglioma, with data anticipated in 2027.
In the U.S., nearly 2,500 people are diagnosed with IDH1-mutant gliomas annually, with more than 95% harboring a mutation in the IDH1 gene.
In other recent news, Daiichi Sankyo reported impressive financial results for the third quarter of fiscal year 2025, exceeding market expectations. The company achieved an earnings per share (EPS) of JPY 46.79, surpassing the projected JPY 39.96. Additionally, Daiichi Sankyo’s revenue reached JPY 1,533.5 billion, slightly above the forecast of JPY 1,533 billion. In another development, Daiichi Sankyo has entered into a collaboration with Tempus AI to enhance their antibody drug conjugate program in oncology. This partnership will utilize Tempus’ AI tools and models to support clinical development through biomarker discovery and patient stratification. Furthermore, Daiichi Sankyo has also partnered with BostonGene to integrate AI into their ADC development, focusing on tumor and immune biology for improved patient selection strategies. These collaborations highlight Daiichi Sankyo’s commitment to advancing its oncology programs through strategic partnerships with AI technology companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.